Reply by Authors.

Reply by Authors.

Tyson, Mark D; Morris, David; Palou, Juan; Rodriguez, Oscar; Mir, Maria Carmen; Dickstein, Rian J; Guerrero-Ramos, Félix; Scarpato, Kristen R; Hafron, Jason M; Messing, Edward M; Cutie, Christopher J; Maffeo, John C; Raybold, Bradley; Chau, Albert; Stromberg, Katharine A; Keegan, Kirk A.

Afiliação

Tyson MD; Mayo Clinic Arizona, Phoenix, Arizona.
Morris D; Urology Associates, Nashville, Tennessee.
Palou J; Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
Rodriguez O; Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
Mir MC; Fundacion Instituto Valenciano de Oncologia, Valencia, Spain.
Dickstein RJ; Chesapeake Urology, Baltimore, Maryland.
Guerrero-Ramos F; University Hospital 12 de Octubre, Madrid, Spain.
Scarpato KR; Vanderbilt University Medical Center, Nashville, Tennessee.
Hafron JM; Michigan Institute of Urology, Troy, Michigan.
Messing EM; University of Rochester, Rochester, New York.
Cutie CJ; Janssen Research & Development, Lexington, Massachusetts.
Maffeo JC; Janssen Research & Development, Lexington, Massachusetts.
Raybold B; Janssen Research & Development, Spring House, Pennsylvania.
Chau A; Datacision Limited, London, United Kingdom.
Stromberg KA; Janssen Research & Development, Raritan, New Jersey.
Keegan KA; Vanderbilt University Medical Center, Nashville, Tennessee.

J Urol ; 209(5): 900, 2023 05.

Article em En | MEDLINE | ID: mdl-37026638

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article